Skip Navigation

European Heart Journal 2003 24(12):1085-1086; doi:10.1016/S0195-668X(03)00232-X
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Brugada, J
Right arrow Articles by Brugada, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brugada, J
Right arrow Articles by Brugada, R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

The ajmaline challenge in Brugada syndrome

A useful tool or misleading information?

J Brugadaa,*, P Brugadab and R Brugadac

a Arrhythmia Section, Cardiovascular Institute, Hospital Clínic, University of Barcelona, Barcelona, Spain
b Cardiovascular Research and Teaching Institute, OLV Hospital, Aalst, Belgium
c Masonic Medical Research Laboratory, NY Utica, USA

* Corresponding author: Josep Brugada, MD, Arrhythmia Section, Cardiovascular Institute, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain. Tel. +34-93-22275551; fax. +34-93-4513045
E-mail address: jbrugada@clinic.ub.es

Received 3 April 2003; accepted 4 April 2003

The first 10% of the full text of this article appears below.

See doi:10.1016/S1095-668X(03)00195-7for the article to which this editorial refers

Ajmaline is a class I antiarrhythmic drug with potent sodium channel blocking effects and a very short half-life which makes it a very useful drug for acute intravenous treatments. The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the Wolff–Parkinson–White syndrome and in well tolerated monomorphic ventricular tachycardias. It has also been used for . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol
Sascha Rolf, Hans-Jürgen Bruns, Thomas Wichter, Paulus Kirchhof, Michael Ribbing, Kristina Wasmer, Matthias Paul, Günter Breithardt, Wilhelm Haverkamp, and Lars Eckardt
EHJ 2003 24: 1104-1112. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 EuropaceHome page
M. Abello, J. L. Merino, R. Peinado, and M. Gnoatto
Negative flecainide test in Brugada syndrome patients with previous positive response
Europace, October 1, 2006; 8(10): 899 - 900.
[Abstract] [Full Text] [PDF]